Clinical trial of indomethacin in Alzheimer's disease
摘要：
In a 6-month, double-blind, placebo-controlled study, 1100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer9s disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (±1.8%), whereas placebo patients declined 8.4% (±2.3%)—a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.
展开
关键词：
Humans Alzheimer Disease Indomethacin Placebos Double-Blind Method Neuropsychological Tests Aged Female Male
DOI：
10.1212/WNL.43.8.1609
被引量：
年份：
1993
Taylor & Francis
doi.org
万方医学
NCBI
NCBI
查看更多
BioMed Central
Oxford Univ Press
APA
Europe PMC
JBC
ResearchGate
mendeley.com
jleukbio.org
arizona.pure.elsevier.com
stroke.ahajournals.org
www.socolar.com
amjmed.com
SAGE
ajcn.nutrition.org
neurology.org
jnm.snmjournals.org
cmaj.ca
futuremedicine.com
jacionline.org
scienceopen.com
jpet.aspetjournals.org
onAcademic
fasebj.org
journalofsurgicalresearch.com
cghjournal.org
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
